Canovai Emilio, Butler Andrew, Clark Susan, Latchford Andrew, Sinha Ashish, Sharkey Lisa, Rutter Charlotte, Russell Neil, Upponi Sara, Amin Irum
Cambridge Centre for Intestinal Rehabilitation and Transplant (CamCIRT), Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom.
Roy Calne Transplant Unit, Cambridge University Hospitals NHS Foundation Trust, Addenbrooke's Hospital, Cambridge, United Kingdom.
Transplant Direct. 2024 Jan 19;10(2):e1571. doi: 10.1097/TXD.0000000000001571. eCollection 2024 Feb.
Desmoid tumors are fibroblastic lesions which often have an unpredictable and variable clinical course. In the context of familial adenomatous polyposis (FAP), these frequently occur intra-abdominally, especially in the small-bowel mesentery resulting in sepsis, fistulation, and invasion of the abdominal wall and retroperitoneum. In selected cases where other modalities have failed, the most radical option is to perform a total enterectomy and intestinal transplantation (ITx). In this study, we present our center's experience of ITx for desmoid in patients with FAP.
We performed a retrospective review of our prospectively collected database between 2007 and 2022. All patients undergoing ITx for FAP-related desmoid were included.
Between October 2007 and September 2023, 144 ITx were performed on 130 patients at our center. Of these, 15 patients (9%) were for desmoid associated with FAP (7 modified multivisceral transplants, 6 isolated ITx, and 2 liver-containing grafts). The median follow-up was 57 mo (8-119); 5-y patient survival was 82%, all with functioning grafts without local desmoid recurrence. These patients presented us with several complex surgical issues, such as loss of abdominal domain, retroperitoneal/abdominal wall involvement, ileoanal pouch-related issues, and the need for foregut resection because of adenomatous disease.
ITx is a viable treatment in selected patients with FAP and extensive desmoid disease. The decision to refer for ITx can be challenging, particularly the timing and sequence of treatment (simultaneous versus sequential exenteration). Delays can result in additional disease burden, such as secondary liver disease or invasion of adjacent structures.
硬纤维瘤是一种纤维母细胞性病变,其临床病程往往不可预测且多变。在家族性腺瘤性息肉病(FAP)的背景下,这些肿瘤常发生于腹腔内,尤其是小肠系膜,可导致脓毒症、肠瘘形成以及腹壁和腹膜后侵犯。在其他治疗方式均失败的特定病例中,最彻底的选择是进行全肠切除术和肠移植(ITx)。在本研究中,我们介绍了我们中心对FAP患者硬纤维瘤进行ITx的经验。
我们对2007年至2022年期间前瞻性收集的数据库进行了回顾性分析。纳入所有因FAP相关硬纤维瘤接受ITx的患者。
2007年10月至2023年9月期间,我们中心对130例患者进行了144次ITx。其中,15例(9%)是针对与FAP相关的硬纤维瘤(7例改良多脏器移植、6例孤立性ITx和2例含肝脏移植物)。中位随访时间为57个月(8 - 119个月);5年患者生存率为82%,所有患者的移植物均功能良好,且硬纤维瘤无局部复发。这些患者给我们带来了几个复杂的外科问题,如腹腔空间丧失、腹膜后/腹壁受累、回肠肛管袋相关问题以及因腺瘤性疾病需要进行前肠切除。
ITx是FAP和广泛硬纤维瘤病患者的一种可行治疗方法。决定进行ITx具有挑战性,特别是治疗的时机和顺序(同步与序贯脏器清除术)。延迟可能导致额外的疾病负担,如继发性肝病或邻近结构侵犯。